
Opinion|Videos|February 10, 2025
Navigating New Treatment Options for Pediatric Atopic Dermatitis Management
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes
2
Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments
3
FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
4
TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD
5








































































